What 7 Analyst Ratings Have To Say About Silence Therapeutics
Portfolio Pulse from Benzinga Insights
Silence Therapeutics (NASDAQ:SLN) has been analyzed by 7 analysts, showing a range of bullish to somewhat bullish sentiments. The average 12-month price target has increased to $57.0 from $43.40. Key analysts from firms like Chardan Capital, Morgan Stanley, and HC Wainwright & Co. have maintained or raised their ratings and price targets. Despite positive analyst ratings, the company faces financial challenges, including a significant revenue decline and low ROE and ROA.
May 17, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics has received predominantly bullish ratings from analysts, with an increased average price target of $57.0. However, the company faces significant financial challenges, including a -55.95% revenue decline and low ROE and ROA.
The predominantly bullish ratings and increased price targets suggest positive short-term sentiment among analysts. However, the company's financial challenges, including a significant revenue decline and low ROE and ROA, may temper the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100